Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Inhibrx, Inc. (INBX) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 778 K | -67,783,000 | 264.39 M | 307.89 M | 295.36 M |
| 2022 | 257 K | -71,796,000 | 232.82 M | 290.88 M | 280.49 M |
| 2021 | 878 K | -60,831,000 | 98.07 M | 150.45 M | 139.11 M |
| 2020 | 615 K | -91,210,000 | 68.27 M | 143.74 M | 132.17 M |
| 2019 | 438 K | 30.19 M | 120.06 M | 26.49 M | 15.56 M |